The study evaluated average cost-sharing for those receiving subsidies in Silver Plans in the 37 states that would be affected by King v. Burwell. In that case, plaintiffs argue that the plain language of the Affordable Care Act does not allow consumers to receive subsidies if they live in states using the federal heath insurance marketplace.
Low-income persons and families receiving subsidies for health coverage under the Affordable Care Act (ACA) have sharply lower out-of-pocket costs than those who do not qualify for the subsides, according to a new report from the Kaiser Family Foundation (KFF).
The study, prepared to show what is at stake in King v. Burwell, explains that cost-sharing subsidies are different from premium tax credits and play a substantial role in holding down costs, especially for those earning 150% of the federal poverty level or less. Consumers who rely on cost-sharing subsidies would be at risk, the study asserts, if the US Supreme Court rules that subsidies in the 37 states using the federal marketplace are no longer allowed. The subsidies are also available in states with their own insurance exchanges, but these consumers would not be affected by the case.
Under the ACA, insurers are required to offer consumers with lower incomes versions of the standard silver plan with lower levels of cost sharing. Those with incomes less than or equal to 150% of the federal poverty level (FPL) can enroll in a plan with a 94% actuarial value; those with 150% to 200% of the FPL can enroll in a plan with 87% actuarial value; those with incomes 200% to 250% of the FPL can enroll in a plan with 73% actuarial value. Higher actuarial value mean there is less cost-sharing. A standard silver plan an actuarial value of 70%, which means the plan covers 70% of the anticipated cost of care and the consumer pays 30%.
The KFF study that due to cost-sharing subsidies, out-of-pocket costs in silver plans vary widely depending on income. For example, the average annual medical and drug deductible in a silver plan ranged from $2556 for someone in a standard plan to $2077 for someone in the 200% to 250% FPL range, to $737 in the 150% to 200% FPL range, to just $229 for those in the 150% FPL or under. Copayments for office visits showed a similar pattern, with the price points at $28, $23, $17, and $14.
The greatest difference was for annual out-of-pocket limits: For standard silver plans, KFF found the average limit was $5826. For those in the 200% to 250% FPL range, the limit was $4624; for $150% to 200% FPL it was $1692, and for 150% FPL and under it was $881.
Plaintiffs who brought King v. Burwell assert that the plain language of the ACA does not permit consumers who live in states without their own exchange from receiving financial subsidies. However, those who defend the current practice, which was upheld in an IRS ruling, say this was the intent of Congress. Numerous friend-of-the-court briefs filed by advocacy groups that supported the ACA say that its intent to grant subsidies to all eligible consumers was clear; otherwise, the groups, say, they would not have supported the law.
The Supreme Court will hear oral arguments in King v. Burwell next month.
Around the Web
New Reports Analyze Cost Sharing in 2015 ACA Marketplace Plans in 37 States
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More